Advanced Therapeutics最新文献_第2页

A Pilot Analysis of Capecitabine Plus PD-1 Antibody as Maintenance Therapy in Advanced or Metastatic Gastric Cancer and the Prognostic Factors 卡培他滨加 PD-1 抗体作为晚期或转移性胃癌维持疗法的试验分析及预后因素分析

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-04 DOI: 10.1002/adtp.202400177

Dong-Liang Chen, Yan Hu, Dong-Sheng Zhang, Feng-Hua Wang

{"title":"A Pilot Analysis of Capecitabine Plus PD-1 Antibody as Maintenance Therapy in Advanced or Metastatic Gastric Cancer and the Prognostic Factors","authors":"Dong-Liang Chen, Yan Hu, Dong-Sheng Zhang, Feng-Hua Wang","doi":"10.1002/adtp.202400177","DOIUrl":"https://doi.org/10.1002/adtp.202400177","url":null,"abstract":"Oxaliplatin-based chemotherapy combined with PD-1 antibody has become the standard treatment for advanced or metastatic gastric cancer. However, the neurotoxicity of oxaliplatin limits its long-term use. A total of 84 patients who received oxaliplatin-based chemotherapy plus PD-1 antibody are enrolled in this study, among which 44 patients are maintained with capecitabine plus PD-1 antibody, whereas the other 40 patients are maintained with capecitabine monotherapy. The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall-survival (OS). Subgroup analysis is performed based on expression of PD-L1 and CXCL12. The median PFS is significantly longer in capecitabine plus PD-1 antibody group (n = 44) than that in capecitabine monotherapy (n = 40) group. The median OS is significantly longer in capecitabine plus PD-1 antibody group than that in capecitabine monotherapy group. Subgroup analysis showed that patients with high expression of PD-L1 or low level of CXCL12 benefited more significantly from capecitabine plus PD-1 antibody maintenance. Maintenance therapy with capecitabine plus PD-1 antibody significantly prolongs the PFS and OS in patients without disease progression after first-line treatment. Patients with high expression of PD-L1 or low expression of CXCL12 benefit more significantly from maintenance therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142587938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combinatory Immunotherapy for Glioblastoma Treatment 治疗胶质母细胞瘤的联合免疫疗法

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-10-02 DOI: 10.1002/adtp.202400217

Muhammad Ijaz, Ikram Hasan, Zhiru Jiang, Zia Ullah, Bilal Aslam, Mohsin Khurshid, Yansun Sun, Bing Guo

{"title":"Combinatory Immunotherapy for Glioblastoma Treatment","authors":"Muhammad Ijaz, Ikram Hasan, Zhiru Jiang, Zia Ullah, Bilal Aslam, Mohsin Khurshid, Yansun Sun, Bing Guo","doi":"10.1002/adtp.202400217","DOIUrl":"https://doi.org/10.1002/adtp.202400217","url":null,"abstract":"Despite advancements in the treatment of glioblastoma, it faces challenges due to tumor heterogeneity, the blood-brain barrier, recurrence, immune evasion, and conventional strategies, leading to low survival and a poor prognosis. Therefore, it is crucial to develop novel, useful treatment strategies for improving brain distribution to overcome blood-brain barriers (BBB) and help the treatment of glioblastoma. Conventional immunotherapy like checkpoint inhibitors, CAR-T cell therapy, monoclonal antibodies, cancer vaccines, and adoptive cell transfer often suffers from low therapeutic outcomes because the singular therapy generally has shortcomings, such as the cold immune microenvironment of brain tumors. In contrast, the emerging combinatory immunotherapy integrated with chemo-immunotherapy, photothermal-immunotherapy, and radio-immunotherapy has shown great promise to modulate tumoral immune microenvironment and boost treatment outcomes. This review discusses the immune microenvironment of GBM, its impact on immunological effects, current immunotherapy methods, and advanced studies. It also introduces combinational GBM immunotherapy with traditional cancer therapies like chemo-immunotherapy, surgery-immunotherapy, photothermal-immunotherapy, and radiotherapy-immunotherapy. In the future, it is anticipated that this article will provide beneficial information and a path for the strategy of innovative, efficient combination immunotherapy in the treatment of glioblastoma.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wireless Light-Emitting Diode-Driven Functional Microneedle Devices for Skin Cancer Therapy 用于皮肤癌治疗的无线发光二极管驱动功能微针设备

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-27 DOI: 10.1002/adtp.202400233

Miranda Oungeun, Supason Wanichwecharungruang, Eijiro Miyako

{"title":"Wireless Light-Emitting Diode-Driven Functional Microneedle Devices for Skin Cancer Therapy","authors":"Miranda Oungeun, Supason Wanichwecharungruang, Eijiro Miyako","doi":"10.1002/adtp.202400233","DOIUrl":"https://doi.org/10.1002/adtp.202400233","url":null,"abstract":"Photodynamic therapy, a noninvasive cancer treatment strategy, is a promising remedy for malignant skin cancers. However, treatment of skin cancer with this method requires sufficient photosensitizer molecules to permeate into cancer cells before illumination for effective activation to induce potent reactive oxygen species for eliminating cancer cells. However, transdermal drug delivery using conventional photosensitizers faces major challenges due to skin barriers, diminishing the effectiveness of drug penetration and therapeutic efficacies. To overcome these limitations, biocompatible, physiologically dissolvable, and optically activatable functional microneedle devices are applied for effective percutaneous penetration of drug molecules into solid tumors in a murine model. The proposed wireless light-emitting diode light-driven functional microneedle device that effectively induces apoptosis of cancer cells and disruption of the tumor area and can enhance in vitro, ex vivo, and in vivo drug-delivery effectiveness for treating skin cancer. The design and strategy of the present functional microneedle devices can help shed light on future advanced cancer therapy.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mucoadhesive Itraconazole Nanocrystals With Precise Control of Surface Charge Incorporated to Chitosan Films for Buccal Drug Delivery 精确控制壳聚糖薄膜表面电荷的粘液黏附性伊曲康唑纳米晶体用于口腔给药

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-25 DOI: 10.1002/adtp.202400209

Chunyang Zhang, Lucia Lopez-Vidal, Jiawen Wang, Achmad Himawan, Ryan F. Donnelly, Alejandro J. Paredes

{"title":"Mucoadhesive Itraconazole Nanocrystals With Precise Control of Surface Charge Incorporated to Chitosan Films for Buccal Drug Delivery","authors":"Chunyang Zhang, Lucia Lopez-Vidal, Jiawen Wang, Achmad Himawan, Ryan F. Donnelly, Alejandro J. Paredes","doi":"10.1002/adtp.202400209","DOIUrl":"https://doi.org/10.1002/adtp.202400209","url":null,"abstract":"Drug delivery to mucosal tissues presents considerable challenges related to the complex nature of the mucus layer protecting such tissues. This aggravates when delivering hydrophobic drugs, often requiring incorporation of drugs to nanoparticles and use of mucoadhesive systems. This paper aimed to develop an antifungal chitosan (CHI)-based film loading itraconazole (ITZ) nanocrystals (NCs) with precisely controlled surface charge for enhanced mucoadhesion. Cationic and anionic ITZ NCs are prepared using wet media milling with mean particle sizes and zeta potentials of 226.9 ± 1.4 nm and 234.0 ± 2.90 nm, and +15.4 ± 2.8 mV and −16.2 ± 1.3 mV, for the cationic and anionic NCs, respectively. Cationic ITZ-NCs exhibits a higher affinity to mucin particles. NCs-loaded films showed stronger mechanical properties and adhesiveness compared with ITZ powder-loaded films. Physicochemical analysis reveals that crystalline properties of the ITZ are preserved, with no drug-excipients interaction. A significantly higher amount of ITZ mucosal deposition is obtained from films containing NCs (1360.23 ± 718.73 µg cm−2) compared with that from films containing ITZ powder (58.83 ± 37.45 µg cm−2). This work demonstrates the feasibility of tailoring the NCs surface, with the resultant systems showing potential for the management of fungal infections in mucosal tissues.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 11","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400209","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142588269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon 用宿主引导疗法（HDTs）治疗传染病，实现最佳健康状态--新视野

IF 4.6 4区医学

Advanced Therapeutics Pub Date : 2024-09-18 DOI: 10.1002/adtp.202400169

Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin

{"title":"Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon","authors":"Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin","doi":"10.1002/adtp.202400169","DOIUrl":"https://doi.org/10.1002/adtp.202400169","url":null,"abstract":"Host‐directed therapies (HDTs) have emerged as a promising strategy to combat viral infections by modifying host factors and immune responses to restrict viral replication and improve patient outcomes. This review summarizes the latest advances and future potential of HDTs in antiviral therapy. With developments in genomics and proteomics, new host targets essential for viral replication have been identified. Gene‐editing tools, such as CRISPR‐Cas9, enable precise manipulation of host genes linked to viral processes, paving the way for innovative HDTs. Emerging approaches, including RNA interference and viral interference, further demonstrate the potential to specifically modify host factors to inhibit viral replication. Additionally, probiotics are being explored for their capacity to enhance immune responses and modulate gut microbiota, offering a natural and safe method for boosting antiviral defenses. Despite these advancements, significant challenges remain, particularly in deciphering complex host–virus interactions and ensuring the safety and efficacy of these therapies. Continued research and clinical evaluation are essential to realize the full potential of HDTs. This review provides a comprehensive overview of current HDT strategies, emphasizing their promise in shaping future antiviral interventions.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"20 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142264863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Ru(II) Polypyridyl Complex Bearing Bathocuproine Ligand is a Potent Chemotherapeutic Agent Against Chemically Induced Skin Cancer Model 含有巴索库络因配体的 Ru(II) 多吡啶络合物是一种针对化学诱导皮肤癌模型的强效化疗药物

IF 4.6 4区医学

Advanced Therapeutics Pub Date : 2024-09-13 DOI: 10.1002/adtp.202400313

Maria George Elias, Stephanie Mehanna, Selim Nasser, Costantine F. Daher, Rony S. Khnayzer

{"title":"A Ru(II) Polypyridyl Complex Bearing Bathocuproine Ligand is a Potent Chemotherapeutic Agent Against Chemically Induced Skin Cancer Model","authors":"Maria George Elias, Stephanie Mehanna, Selim Nasser, Costantine F. Daher, Rony S. Khnayzer","doi":"10.1002/adtp.202400313","DOIUrl":"https://doi.org/10.1002/adtp.202400313","url":null,"abstract":"Ruthenium‐based compounds have emerged as prospective chemotherapeutic candidates with various mechanisms of action and minimal associated side effects compared to conventional metal‐based chemotherapeutics. The present study explores the chemotherapeutic potential of [Ru(bpy)2BC]Cl2 (where bpy = 2,2′‐bipyridine and BC = bathocuproine) or RuBC on a 7,12‐dimethylbenz[a]anthracene/12‐o‐tetradecanoylphorbol‐13‐acetate (DMBA/TPA) murine skin carcinogenesis model. RuBC is well tolerated up to 2.5 mg kg−1; no changes in body weight, behavior or serum biochemistry are observed. Following IP injections, the bioavailability of the complex is high in the plasma, which favors its accumulation in the organs. Efficacy studies demonstrated that RuBC has a significant anticancer activity by week 7 of treatment and a decrease in tumor size is observed by week 6 in all tested groups. Based on western blot analyses, apoptosis through the intrinsic pathway is suggested as the main mechanism of cell death. A downregulation of the MAPK pathway is also observed. The results indicate that RuBC is a multi‐mechanistic chemotherapeutic drug that has promising anticancer effects with significant potential for further investigation.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 1","pages":""},"PeriodicalIF":4.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142264865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Administration Self-Boosting Microneedle Patch for the Treatment of Obesity (Adv. Therap. 9/2024) 用于治疗肥胖症的单次给药自增效微针贴片（Adv. Therap.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-11 DOI: 10.1002/adtp.202470019

Parbeen Singh, Tra Vinikoor, Nidhi Sharma, Nicole Nelson, Somasundaram Prasadh, Ralph Oiknine, Thanh Duc Nguyen

引用次数: 0

Zeolitic Imidazolate Frameworks Based Anticancer Drug Delivery System Associated with Dual Action of Surface Charge and Lewis Base Ligand (Adv. Therap. 9/2024) 基于沸石咪唑框架的抗癌药物输送系统与表面电荷和路易斯碱配体的双重作用有关（Adv.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-11 DOI: 10.1002/adtp.202470017

Wenjuan Yang, Lingling Tian, Ning Zhao, Lingyan Feng, Bingpu Zhou, Yongheng Zhu, Xinghua Gao, Yuan Zhang

引用次数: 0

Targeting Glioblastoma Tumor Hyaluronan to Enhance Therapeutic Interventions that Regulate Metabolic Cell Properties 以胶质母细胞瘤肿瘤透明质酸为靶点，加强调节细胞代谢特性的治疗干预措施

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-11 DOI: 10.1002/adtp.202400041

Edward R Neves, Achal Anand, Joseph Mueller, Roddel A Remy, Hui Xu, Kim A Selting, Jann N Sarkaria, Brendan AC Harley, Sara Pedron-Haba

{"title":"Targeting Glioblastoma Tumor Hyaluronan to Enhance Therapeutic Interventions that Regulate Metabolic Cell Properties","authors":"Edward R Neves, Achal Anand, Joseph Mueller, Roddel A Remy, Hui Xu, Kim A Selting, Jann N Sarkaria, Brendan AC Harley, Sara Pedron-Haba","doi":"10.1002/adtp.202400041","DOIUrl":"10.1002/adtp.202400041","url":null,"abstract":"Despite extensive advances in cancer research, glioblastoma (GBM) still remains a very locally invasive and thus challenging tumor to treat, with a poor median survival. Tumor cells remodel their microenvironment and utilize extracellular matrix to promote invasion and therapeutic resistance. It is aimed here to determine how GBM cells exploit hyaluronan (HA) to maintain proliferation using ligand-receptor dependent and ligand-receptor independent signaling. Tissue engineering approaches are used to recreate the 3D tumor microenvironment in vitro, then analyze shifts in metabolism, hyaluronan secretion, HA molecular weight distribution, as well as hyaluronan synthetic enzymes (HAS) and hyaluronidases (HYAL) activity in an array of patient-derived xenograft GBM cells. It is revealed that endogenous HA plays a role in mitochondrial respiration and cell proliferation in a tumor subtype-dependent manner. A tumor-specific combination treatment of HYAL and HAS inhibitors is proposed to disrupt the HA stabilizing role in GBM cells. Taken together, these data shed light on the dual metabolic and ligand – dependent signaling roles of hyaluronan in glioblastoma.","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"7 10","pages":""},"PeriodicalIF":3.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.202400041","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142184317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Information (Adv. Therap. 9/2024) 发行信息（Adv. Therap.）

IF 3.7 4区医学

Advanced Therapeutics Pub Date : 2024-09-11 DOI: 10.1002/adtp.202470018

引用次数: 0